Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …

In 2006 HPV vaccination was licensed for primary prevention of HPV related disease in
young females.[1]. Only a few years after, immunological and clinical studies offered new …

Objective To explore the efficacy of human papillomavirus (HPV) vaccination on the risk of
HPV infection and recurrent diseases related to HPV infection in individuals undergoing …

Oropharyngeal cancer (OPC) has become the leading site for human papillomavirus (HPV)–
associated cancers in humans. It is an epidemic that remains relatively unfamiliar to most …

Human papillomavirus (HPV)-related screening technologies and HPV vaccination offer
enormous potential for cancer prevention, notably prevention of cervical cancer. The …

Objective: The aim of this meta-analysis was to discuss evidence supporting the efficacy of
adjuvant human papillomavirus (HPV) vaccination in reducing the risk of recurrent cervical …

OBJECTIVE: To perform a systematic review and meta-analysis evaluating the efficacy of
adjuvant human papillomavirus (HPV) vaccination in preventing recurrent cervical …

Introduction Human papillomavirus (HPV) vaccination is essential for cervical cancer
prevention. However, the value of HPV vaccination in the context excisional treatment of …

Prophylactic vaccines have been found to be highly effective in preventing infection and pre-
invasive and invasive cervical, vulvovaginal and anal disease caused by the vaccine types …